Real-world data for health technology assessment for reimbursement decisions in Asia: Current landscape and a way forward

Jing Lou; Sarin Kc; Kai Yee Toh; Saudamini Dabak; Amanda Adler; Jeonghoon Ahn; DIana Beatriz S. Bayani; Kelvin Chan; Dechen Choiphel; Brandon Chua; Anne Julienne Genuino; Anna Melissa Guerrero; Brendon Kearney; Lydia Wenxin Lin; Yuehua Liu; Ryota Nakamura; Fiona Pearce; Shankar Prinja; Raoh Fang Pwu; Asrul Akmal Shafie; Binyan Sui; Auliya Suwantika; Yot Teerawattananon; Sean Tunis; Hui Min Wu; John Zalcberg; Kun Zhao; Wanrudee Isaranuwatchai; Hwee Lin Wee

doi:10.1017/S0266462320000628

Real-world data for health technology assessment for reimbursement decisions in Asia: Current landscape and a way forward

Jing Lou, Sarin Kc, Kai Yee Toh, Saudamini Dabak, Amanda Adler, Jeonghoon Ahn, DIana Beatriz S. Bayani, Kelvin Chan, Dechen Choiphel, Brandon Chua, Anne Julienne Genuino, Anna Melissa Guerrero, Brendon Kearney, Lydia Wenxin Lin, Yuehua Liu, Ryota Nakamura, Fiona Pearce, Shankar Prinja, Raoh Fang Pwu, Asrul Akmal ShafieBinyan Sui, Auliya Suwantika, Yot Teerawattananon, Sean Tunis, Hui Min Wu, John Zalcberg, Kun Zhao, Wanrudee Isaranuwatchai, Hwee Lin Wee

Department of Health Convergence

Research output: Contribution to journal › Review article › peer-review

22 Scopus citations

Abstract

There is growing interest globally in using real-world data (RWD) and real-world evidence (RWE) for health technology assessment (HTA). Optimal collection, analysis, and use of RWD/RWE to inform HTA requires a conceptual framework to standardize processes and ensure consistency. However, such framework is currently lacking in Asia, a region that is likely to benefit from RWD/RWE for at least two reasons. First, there is often limited Asian representation in clinical trials unless specifically conducted in Asian populations, and RWD may help to fill the evidence gap. Second, in a few Asian health systems, reimbursement decisions are not made at market entry; thus, allowing RWD/RWE to be collected to give more certainty about the effectiveness of technologies in the local setting and inform their appropriate use. Furthermore, an alignment of RWD/RWE policies across Asia would equip decision makers with context-relevant evidence, and improve timely patient access to new technologies. Using data collected from eleven health systems in Asia, this paper provides a review of the current landscape of RWD/RWE in Asia to inform HTA and explores a way forward to align policies within the region. This paper concludes with a proposal to establish an international collaboration among academics and HTA agencies in the region: the REAL World Data In ASia for HEalth Technology Assessment in Reimbursement (REALISE) working group, which seeks to develop a non-binding guidance document on the use of RWD/RWE to inform HTA for decision making in Asia.

Original language	English
Pages (from-to)	474-480
Number of pages	7
Journal	International Journal of Technology Assessment in Health Care
Volume	36
Issue number	5
DOIs	https://doi.org/10.1017/S0266462320000628
State	Published - Oct 2020

Bibliographical note

Funding Information:
Hwee-Lin Wee has received grants from Pfizer (Singapore), Roche (Singapore), Novartis (Singapore), and Johnson & Johnson (Singapore) to conduct research and workshops.

Funding Information:
This work was supported by an unrestricted grant from The International Decision Support Initiative (iDSI, www.idsihealth.org ) (grant number: OPP1134345), a global network of health, policy, and economic expertise, working to achieve Universal Health Coverage and the health Sustainable Development Goal (SDG 3), and which supports countries to get the best value for money from health spending. iDSI receives funding support from the Bill & Melinda Gates Foundation, the UK Department for International Development, and the Rockefeller Foundation. Ryota Nakamura was also supported by the Japan Society for the Promotion of Science KAKENHI (grant number: 18H00862). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings, interpretations, and conclusions expressed in this article do not necessarily reflect the views of the aforementioned funding agencies. A representative from iDSI participated in the first REASLISE working group meeting as an observer.

Publisher Copyright:
Copyright © The Author(s), 2020. Published by Cambridge University Press.

Keywords

Asia
Cost-effectiveness analysis
Health technology assessment
Real-world data
Real-world evidence

Access to Document

10.1017/S0266462320000628

Cite this

Lou, J., Kc, S., Toh, K. Y., Dabak, S., Adler, A., Ahn, J., Bayani, DI. B. S., Chan, K., Choiphel, D., Chua, B., Genuino, A. J., Guerrero, A. M., Kearney, B., Lin, L. W., Liu, Y., Nakamura, R., Pearce, F., Prinja, S., Pwu, R. F., ... Wee, H. L. (2020). Real-world data for health technology assessment for reimbursement decisions in Asia: Current landscape and a way forward. International Journal of Technology Assessment in Health Care, 36(5), 474-480. https://doi.org/10.1017/S0266462320000628

@article{6d181e4e62b74767b6c202ec0d444fd7,

title = "Real-world data for health technology assessment for reimbursement decisions in Asia: Current landscape and a way forward",

abstract = "There is growing interest globally in using real-world data (RWD) and real-world evidence (RWE) for health technology assessment (HTA). Optimal collection, analysis, and use of RWD/RWE to inform HTA requires a conceptual framework to standardize processes and ensure consistency. However, such framework is currently lacking in Asia, a region that is likely to benefit from RWD/RWE for at least two reasons. First, there is often limited Asian representation in clinical trials unless specifically conducted in Asian populations, and RWD may help to fill the evidence gap. Second, in a few Asian health systems, reimbursement decisions are not made at market entry; thus, allowing RWD/RWE to be collected to give more certainty about the effectiveness of technologies in the local setting and inform their appropriate use. Furthermore, an alignment of RWD/RWE policies across Asia would equip decision makers with context-relevant evidence, and improve timely patient access to new technologies. Using data collected from eleven health systems in Asia, this paper provides a review of the current landscape of RWD/RWE in Asia to inform HTA and explores a way forward to align policies within the region. This paper concludes with a proposal to establish an international collaboration among academics and HTA agencies in the region: the REAL World Data In ASia for HEalth Technology Assessment in Reimbursement (REALISE) working group, which seeks to develop a non-binding guidance document on the use of RWD/RWE to inform HTA for decision making in Asia.",

keywords = "Asia, Cost-effectiveness analysis, Health technology assessment, Real-world data, Real-world evidence",

author = "Jing Lou and Sarin Kc and Toh, {Kai Yee} and Saudamini Dabak and Amanda Adler and Jeonghoon Ahn and Bayani, {DIana Beatriz S.} and Kelvin Chan and Dechen Choiphel and Brandon Chua and Genuino, {Anne Julienne} and Guerrero, {Anna Melissa} and Brendon Kearney and Lin, {Lydia Wenxin} and Yuehua Liu and Ryota Nakamura and Fiona Pearce and Shankar Prinja and Pwu, {Raoh Fang} and Shafie, {Asrul Akmal} and Binyan Sui and Auliya Suwantika and Yot Teerawattananon and Sean Tunis and Wu, {Hui Min} and John Zalcberg and Kun Zhao and Wanrudee Isaranuwatchai and Wee, {Hwee Lin}",

note = "Funding Information: Hwee-Lin Wee has received grants from Pfizer (Singapore), Roche (Singapore), Novartis (Singapore), and Johnson & Johnson (Singapore) to conduct research and workshops. Funding Information: This work was supported by an unrestricted grant from The International Decision Support Initiative (iDSI, www.idsihealth.org ) (grant number: OPP1134345), a global network of health, policy, and economic expertise, working to achieve Universal Health Coverage and the health Sustainable Development Goal (SDG 3), and which supports countries to get the best value for money from health spending. iDSI receives funding support from the Bill & Melinda Gates Foundation, the UK Department for International Development, and the Rockefeller Foundation. Ryota Nakamura was also supported by the Japan Society for the Promotion of Science KAKENHI (grant number: 18H00862). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings, interpretations, and conclusions expressed in this article do not necessarily reflect the views of the aforementioned funding agencies. A representative from iDSI participated in the first REASLISE working group meeting as an observer. Publisher Copyright: Copyright {\textcopyright} The Author(s), 2020. Published by Cambridge University Press.",

year = "2020",

month = oct,

doi = "10.1017/S0266462320000628",

language = "English",

volume = "36",

pages = "474--480",

journal = "International Journal of Technology Assessment in Health Care",

issn = "0266-4623",

publisher = "Cambridge University Press",

number = "5",

}

Lou, J, Kc, S, Toh, KY, Dabak, S, Adler, A, Ahn, J, Bayani, DIBS, Chan, K, Choiphel, D, Chua, B, Genuino, AJ, Guerrero, AM, Kearney, B, Lin, LW, Liu, Y, Nakamura, R, Pearce, F, Prinja, S, Pwu, RF, Shafie, AA, Sui, B, Suwantika, A, Teerawattananon, Y, Tunis, S, Wu, HM, Zalcberg, J, Zhao, K, Isaranuwatchai, W & Wee, HL 2020, 'Real-world data for health technology assessment for reimbursement decisions in Asia: Current landscape and a way forward', International Journal of Technology Assessment in Health Care, vol. 36, no. 5, pp. 474-480. https://doi.org/10.1017/S0266462320000628

TY - JOUR

T1 - Real-world data for health technology assessment for reimbursement decisions in Asia

T2 - Current landscape and a way forward

AU - Lou, Jing

AU - Kc, Sarin

AU - Toh, Kai Yee

AU - Dabak, Saudamini

AU - Adler, Amanda

AU - Ahn, Jeonghoon

AU - Bayani, DIana Beatriz S.

AU - Chan, Kelvin

AU - Choiphel, Dechen

AU - Chua, Brandon

AU - Genuino, Anne Julienne

AU - Guerrero, Anna Melissa

AU - Kearney, Brendon

AU - Lin, Lydia Wenxin

AU - Liu, Yuehua

AU - Nakamura, Ryota

AU - Pearce, Fiona

AU - Prinja, Shankar

AU - Pwu, Raoh Fang

AU - Shafie, Asrul Akmal

AU - Sui, Binyan

AU - Suwantika, Auliya

AU - Teerawattananon, Yot

AU - Tunis, Sean

AU - Wu, Hui Min

AU - Zalcberg, John

AU - Zhao, Kun

AU - Isaranuwatchai, Wanrudee

AU - Wee, Hwee Lin

N1 - Funding Information: Hwee-Lin Wee has received grants from Pfizer (Singapore), Roche (Singapore), Novartis (Singapore), and Johnson & Johnson (Singapore) to conduct research and workshops. Funding Information: This work was supported by an unrestricted grant from The International Decision Support Initiative (iDSI, www.idsihealth.org ) (grant number: OPP1134345), a global network of health, policy, and economic expertise, working to achieve Universal Health Coverage and the health Sustainable Development Goal (SDG 3), and which supports countries to get the best value for money from health spending. iDSI receives funding support from the Bill & Melinda Gates Foundation, the UK Department for International Development, and the Rockefeller Foundation. Ryota Nakamura was also supported by the Japan Society for the Promotion of Science KAKENHI (grant number: 18H00862). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings, interpretations, and conclusions expressed in this article do not necessarily reflect the views of the aforementioned funding agencies. A representative from iDSI participated in the first REASLISE working group meeting as an observer. Publisher Copyright: Copyright © The Author(s), 2020. Published by Cambridge University Press.

PY - 2020/10

Y1 - 2020/10

N2 - There is growing interest globally in using real-world data (RWD) and real-world evidence (RWE) for health technology assessment (HTA). Optimal collection, analysis, and use of RWD/RWE to inform HTA requires a conceptual framework to standardize processes and ensure consistency. However, such framework is currently lacking in Asia, a region that is likely to benefit from RWD/RWE for at least two reasons. First, there is often limited Asian representation in clinical trials unless specifically conducted in Asian populations, and RWD may help to fill the evidence gap. Second, in a few Asian health systems, reimbursement decisions are not made at market entry; thus, allowing RWD/RWE to be collected to give more certainty about the effectiveness of technologies in the local setting and inform their appropriate use. Furthermore, an alignment of RWD/RWE policies across Asia would equip decision makers with context-relevant evidence, and improve timely patient access to new technologies. Using data collected from eleven health systems in Asia, this paper provides a review of the current landscape of RWD/RWE in Asia to inform HTA and explores a way forward to align policies within the region. This paper concludes with a proposal to establish an international collaboration among academics and HTA agencies in the region: the REAL World Data In ASia for HEalth Technology Assessment in Reimbursement (REALISE) working group, which seeks to develop a non-binding guidance document on the use of RWD/RWE to inform HTA for decision making in Asia.

AB - There is growing interest globally in using real-world data (RWD) and real-world evidence (RWE) for health technology assessment (HTA). Optimal collection, analysis, and use of RWD/RWE to inform HTA requires a conceptual framework to standardize processes and ensure consistency. However, such framework is currently lacking in Asia, a region that is likely to benefit from RWD/RWE for at least two reasons. First, there is often limited Asian representation in clinical trials unless specifically conducted in Asian populations, and RWD may help to fill the evidence gap. Second, in a few Asian health systems, reimbursement decisions are not made at market entry; thus, allowing RWD/RWE to be collected to give more certainty about the effectiveness of technologies in the local setting and inform their appropriate use. Furthermore, an alignment of RWD/RWE policies across Asia would equip decision makers with context-relevant evidence, and improve timely patient access to new technologies. Using data collected from eleven health systems in Asia, this paper provides a review of the current landscape of RWD/RWE in Asia to inform HTA and explores a way forward to align policies within the region. This paper concludes with a proposal to establish an international collaboration among academics and HTA agencies in the region: the REAL World Data In ASia for HEalth Technology Assessment in Reimbursement (REALISE) working group, which seeks to develop a non-binding guidance document on the use of RWD/RWE to inform HTA for decision making in Asia.

KW - Asia

KW - Cost-effectiveness analysis

KW - Health technology assessment

KW - Real-world data

KW - Real-world evidence

UR - http://www.scopus.com/inward/record.url?scp=85096157673&partnerID=8YFLogxK

U2 - 10.1017/S0266462320000628

DO - 10.1017/S0266462320000628

M3 - Review article

C2 - 32928330

AN - SCOPUS:85096157673

SN - 0266-4623

VL - 36

SP - 474

EP - 480

JO - International Journal of Technology Assessment in Health Care

JF - International Journal of Technology Assessment in Health Care

IS - 5

ER -

Real-world data for health technology assessment for reimbursement decisions in Asia: Current landscape and a way forward

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this